• In June, Emgality (galcanezumab) became the first CGRP antibody to be approved for episodic cluster headache prevention in the USA, and the following month rimegepant moved into trigeminal neuralgia trials.
• With migraine the focus of World Brain Day for the first time, CGRP Forum Editors, David Dodick and Peter Goadsby, were among leading migraine specialists urging policymakers to prioritise migraine and achieve benefits for patients and society.
• Reporting data from three major congresses in Europe and the USA, the Forum brought together latest long term and real world data for anti—CGRP therapies — demonstrating their sustained efficacy and how they are taking their place in clinical practice.
• For clinicians considering whether to prescribe anti-CGRP therapies for paediatric patients, the Forum‘s latest Hot Topic presented an accessible guide to the evidence.
• And finally… new this week on the Forum, CGRP in the Journals is a useful service for members. It summarises some of the most important CGRP publications of the last 12 months and will be regularly updated.

Read CGRP in the Journals here »

Catch up at:

Is anti-CGRP therapy approved for your patients?

Emgality (galcanezumab) gains US approval for episodic cluster headache treatment

Rimegepant moves into trigeminal neuralgia trials

Wake up to World Brain Day — 22 July 2019

Erenumab real-world experience supports clinical trial data

Fremanezumab demonstrates 10-year cost effectiveness

What do clinicians need to know when prescribing CGRP inhibitors to children and adolescents?